Published in Cancer Weekly, July 17th, 2007
Under the terms of a newly established collaboration, Algeta has initiated a feasibility study agreement with an undisclosed partner specialised in antibody-based therapeutics. The collaboration is aimed at linking the alpha emitter Thorium-227 to tumor-selective antibodies developed by the partner. Pursuing a jointly developed and managed research collaboration, both parties will upon completion assess the development and commercialization potential of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.